作者
Arash Heidari, Pouya M Sharif, Nima Rezaei
发表日期
2021/12/1
来源
Current Pharmaceutical Design
卷号
27
期号
46
页码范围
4650-4662
出版商
Bentham Science Publishers
简介
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, causing many deaths each year. The life expectancy of patients from the time of diagnosis does not exceed 15 months. Tumoral cells are generally surrounded by a bed of tumor microenvironment (TME), composed of various components such as different immune cells, stromal cells, and blood vessels. Previous studies on the treatment of this tumor have generally focused on cancerous cells and, therefore, have introduced conventional therapies for eradicating this tumor, including maximal safe surgery, chemotherapy with temozolomide (TMZ), and radiotherapy. Despite treatment with this method, tumors almost always recur, and life expectancy has not increased much. Recently, due to the discovery of the various roles of immune cells (including tumor-associated macrophages or TAMs) in the pathogenesis of this disease, the …
引用总数
学术搜索中的文章
A Heidari, PM Sharif, N Rezaei - Current Pharmaceutical Design, 2021